Boncare 150 mg (Tablet)
1 tablet kit: ৳ 1,203.61
Medicine Details
| Category | Details |
|---|---|
| Generic | Ibandronic acid |
| Company | Orion pharma ltd |
Indications
- Treatment of osteoporosis in women(postmenopausal)
- Prevention of osteoporosis in women(postmenopausal)
- Prevention and treatment of osteoporosis in men
Pharmacology
- Inhibition of bone resorption
- Prevents experimentally induced bone destruction
- Highly potent bisphosphonate
- Inhibits osteoclast activity
- Reduces bone resorption
Dosage administration
- Recommended dose: 150 mg once a month
- Tablet should be taken with plain water while sitting or standing upright
- Should not lie down for 60 minutes after taking
- Should not chew or suck the tablet
- Supplemental calcium or vitamin D may be required
Interactions
- Likely interference with calcium supplements and antacids
- No interaction with tamoxifen or hormone replacement therapy
- Increase in bioavailability with i.v. ranitidine
- No significant drug interactions expected
- Similar upper gastrointestinal event incidence with histamine blockers or proton pump inhibitors
Contraindications
- Hypersensitivity to ibandronic acid or its excipients
- Uncorrected hypocalcemia
- Abnormalities of the esophagus delaying esophageal emptying
- Inability to stand or sit upright for at least 60 minutes
Side effects
- Dyspepsia
- Nausea
- Diarrhea
- Abdominal pain
- Muscle aches
- Headaches
- Dizziness
Pregnancy lactation
- Not recommended during pregnancy
- No clinical experience in pregnant women
- Not recommended during lactation
- Small concentration in breast milk
Precautions warnings
- Treat hypocalcemia before therapy
- Caution in patients with upper gastrointestinal problems
- Potential for esophageal adverse experiences
- Possible gastric and duodenal ulcers with oral bisphosphonate use
- Risk of osteonecrosis of the jaw
Special populations
- No dosage adjustment in mild or moderate renal impairment
- No dosage adjustment in hepatic impairment
- No dosage adjustment in elderly
- Safety and efficacy not established in children under 18 years old
Overdose effects
- Oral overdosage may result in upper gastrointestinal adverse events
- Milk or antacids should be given to bind Boncare
- Risk of esophageal irritation
Therapeutic class
- Bisphosphonate preparations
Storage conditions
- Keep below 30°C
- Away from light and moisture
- Keep out of the reach of children